COMP <GO>
HRMY vs AGIO // GROSS PROFIT MARGIN
Harmony Biosciences Holdings Inc. (NASDAQ) VS. Agios Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: HRMY 7
— AGIO 3
▲ GROSS PROFIT MARGIN LEADER: AGIO
LAST: $38.59 (+0.23%) • MKT CAP: $2.25B
gross-margins
77.20%
LAST: $37.23 (-2.33%) • MKT CAP: $2.22B
gross-margins
88.30%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (HRMY VS. AGIO)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | HRMY | AGIO | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin ACTIVE | 77.20% | 88.30% | -11.10 | AGIO | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 63.00% | -33.80% | +96.80 | HRMY | /roic <GO> |
| EV/EBITDA & P/E Valuation | 7.8x | — | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 15.48% | -16.97% | +32.45 | HRMY | /fcf-yield <GO> |
| Operating Margin | 24.00% | -60.00% | +84.00 | HRMY | /operating-margins <GO> |
| Net Profit Margin | 18.30% | -60.00% | +78.30 | HRMY | /net-margins <GO> |
| Revenue Growth (YoY) | 21.50% | 48.00% | -26.50 | AGIO | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 5.38 | 11.84 | -6.46 | AGIO | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 4/9 | +5.00 | HRMY | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 51.1 | 37.2 | +13.83 | HRMY | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | — | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 11.9x | — | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $2.25B | $2.22B | $24.6M | HRMY | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | HRMY REV | AGIO REV | HRMY GROSS % | AGIO GROSS % | HRMY FCF | AGIO FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $868.5M | $54.0M | 77.2% | 88.3% | $347.9M | -$377.3M |
| FY 2024 | $714.7M | $36.5M | 78.1% | 88.6% | $218.7M | -$391.5M |
| FY 2023 | $582.0M | $26.8M | — | — | $219.4M | -$296.1M |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
HRMY // BETA —
AGIO // BETA —